DUBLIN--(BUSINESS WIRE)--The "Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.
This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand.
The report profiles 34 companies including many key and niche players such as:
- AbbVie Inc. (USA)
- Actinium Pharmaceuticals, Inc. (USA)
- Agios Pharmaceuticals, Inc. (USA)
- Amgen Inc. (USA)
- Astellas Pharma Inc. (Japan)
- Astex Pharmaceuticals, Inc. (USA)
- Celgene Corporation (USA)
- CTI BioPharma Corp. (USA)
- Cyclacel Pharmaceuticals, Inc. (USA)
- Daiichi Sankyo Company Limited (Japan)
- F. Hoffmann-La Roche AG (Switzerland)
- Immune Pharmaceuticals Inc. (USA)
- Janssen-Cilag Limited (UK)
- Jazz Pharmaceuticals plc (Ireland)
- MEI Pharma, Inc. (USA)
- Merus N.V. (The Netherlands)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- Seattle Genetics, Inc. (USA)
- Stemline Therapeutics, Inc. (USA)
- Sunesis Pharmaceuticals, Inc. (USA)
- Tolero Pharmaceuticals, Inc. (USA)
Key Topics Covered
1. Outlook
2. Market Dynamics
3. Acute Myeloid Leukemia
4. Treatment Overview
5. Drug Approvals/Clinical Studies
6. Recent Industry Activity
7. Focus on Select Players
8. Global Market Perspective
Total Companies Profiled: 69 (including Divisions/Subsidiaries 73)
- The United States (40)
- Canada (3)
- Japan (3)
-
Europe (24)
- France (3)
- Germany (2)
- The United Kingdom (5)
- Spain (1)
- Rest of Europe (13)
- Asia-Pacific (Excluding Japan) (1)
- Middle East (2)
For more information about this report visit https://www.researchandmarkets.com/research/8wl74p/global_strategic?w=4
